Disqualifying dispositions of incentive stock options Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Disqualifying Dispositions Of Incentive Stock Options Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Disqualifying Dispositions Of Incentive Stock Options SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Supplemental Cash Flow Information [Abstract] Net Loss Per Common Share Earnings Per Share, Policy [Policy Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Leasehold improvements Leasehold Improvements [Member] Net loss Net loss Net Income (Loss) Attributable to Parent Operating lease right-of-use assets Operating ROU assets Operating Lease, Right-of-Use Asset Short-term investments Debt Securities, Available-for-sale, Current Net operating loss carryforwards Deferred Tax Assets, Operating Loss Carryforwards Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Accrued compensation and related expenses Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Proceeds from the sale of future royalties Proceeds From Sale Of Advance Future Royalties Proceeds From Sale Of Advance Future Royalties Receivables from collaborative partners Increase (Decrease) in Contract with Customer, Asset Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Proceeds from the sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Schedule of Royalty Transaction Activity Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Foreign Currency of Foreign Operations Foreign Currency Transactions and Translations Policy [Policy Text Block] Other long-term assets Other Assets, Noncurrent Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties [Line Items] Liabilities Related To Sale Of Future Royalties Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Shares reserved for future award grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Retirement Benefits [Abstract] Retirement Benefits [Abstract] By the end of 2026 First Installment [Member] First Installment Net increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Entity File Number Entity File Number Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Issued and Outstanding: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Future minimum annual cash obligations, Thereafter Other Commitment, To Be Paid, After Year One Other Commitment, To Be Paid, After Year One Forfeitures and cancellations (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Certificates of Deposit Certificates of Deposit [Member] Interest income Interest Income, Other Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net Weighted-average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Options to purchase common stock (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Research and development Research and Development Expense [Member] GSK GlaxoSmithKline [Member] GlaxoSmithKline First MAA approval - first indication First Marketing Authorization Application Approval First Indication [Member] First Marketing Authorization Application Approval First Indication Title of Individual [Domain] Title of Individual [Domain] Award Type [Domain] Award Type [Domain] IND clearance from the FDA Clearance Of Investigational New Drug From FDA [Member] Clearance Of Investigational New Drug From FDA [Member] Local Phone Number Local Phone Number Monthly base rate (usd per sqft) Rent Per Square Foot Rent Per Square Foot Credit Facility [Domain] Credit Facility [Domain] ASSETS Assets [Abstract] Schedule of Available-for-sale Investments Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Weighted-Average Remaining Contractual Term and Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Operating Loss Carryforwards [Line Items] Operating Loss Carryforwards [Line Items] Stock options exercisable, ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Remaining maturity (in years) Available-for-sale Debt Securities, Remaining Maturity Available-for-sale Debt Securities, Remaining Maturity Deferred Tax Assets, Operating Loss Carryforwards, Domestic Deferred Tax Assets, Operating Loss Carryforwards, Domestic New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Maximum milestone payments per target Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Revenue Recognition, Milestone Method, Maximum Revenue Per Milestone Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2021 and December 31, 2020, respectively Preferred Stock, Value, Issued Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Stock options (in shares) Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated Deficit Retained Earnings [Member] Deferred Revenue Arrangement, by Type [Table] Deferred Revenue Arrangement, by Type [Table] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Lease term (in months) Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Area of leased property (sqft) Area of Real Estate Property Royalty Agreement, above $1. 0 billion Royalty Agreement, Above $1. 0 billion [Member] Royalty Agreement, Above $1. 0 billion ROU asset Deferred Tax Liabilities, Leasing Arrangements Other Liabilities Disclosure [Abstract] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Milestone payments, contingent upon achievement of specified levels of worldwide sales (up to) Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Revenue Recognition, Milestone Method, Contingent Upon Achievement Of Specified Levels Of Worldwide Sales Amounts accrued for property and equipment Capital Expenditures Incurred but Not yet Paid Leased assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Schedule of Components of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Return to provision adjustment Effective Income Tax Rate Reconciliation, Tax Settlement, Amount Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Filing of the first BLA - second indication Filing Of Biologics License Application Second Indication [Member] Filing Of Biologics License Application Second Indication Tax Period [Domain] Tax Period [Domain] Loss per share, basic (in dollars per share) Earnings Per Share, Basic Royalty Purchase Agreement Royalty Purchase Agreement [Member] Royalty Purchase Agreement 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three First BLA approval - first indication First Biologics License Application Approval D M M R E C [Member] First Biologics License Application Approval D M M R E C Permanent items Effective Income Tax Rate Reconciliation, Tax Exempt Income, Amount Milestone payments, contingent upon preclinical and clinical trial events (up to) Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Revenue Recognition, Milestone Method, Contingent Upon Preclinical And Clinical Trial Events Cash paid for amounts included in the measurement of lease liabilities Operating Lease, Payments Payments for issuance costs related to the sale of future royalties Payments Of Advance Future Royalties Issuance Costs Payments Of Advance Future Royalties Issuance Costs Non-cash interest expense Other Noncash Income (Expense) Fixed assets Deferred Tax Liabilities, Property, Plant and Equipment Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Stock-based compensation Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Share-based Compensation And Issuance Of Stock And Warrants For Services Or Claims Receivables from collaborative partners Receivables, Net, Current Entity Voluntary Filers Entity Voluntary Filers Plan Name [Axis] Plan Name [Axis] Quoted Market Prices for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Weighted-average number of shares outstanding: Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] State income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Liabilities Related To Sale Of Future Royalties [Table Text Block] Liabilities Related To Sale Of Future Royalties [Table] Liabilities Related To Sale Of Future Royalties Entity Small Business Entity Small Business Number of outstanding research and development targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Revenue Recognition, Milestone Method, Number Of Outstanding Research And Development Targets Increase related to current year tax positions Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Total liabilities and stockholders’ equity Liabilities and Equity Other Other Accrued Liabilities, Current Excess tax benefits associated with the exercise of non-qualified stock options Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount 2026 Lessee, Operating Lease, Liability, to be Paid, Year Five Sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-sale Exercises (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Additional paid in capital Additional Paid in Capital Agency securities US Government Agencies Debt Securities [Member] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Deferred Revenue Arrangement [Line Items] Proceeds from sale of future royalties Proceeds From Advance Future Royalties Proceeds From Advance Future Royalties LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Unrecognized tax benefits that if recognized and realized would affect the effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Royalty Agreement Royalty Agreement [Member] Royalty Agreement Operating expenses: Operating Expenses [Abstract] Anti-PD-1 (CC-90006) AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] AnaptysBio-Generated Anti-PD-1 Antagonist Antibody (CC-90006) [Member] Anti-LAG-3 (GSK40974386) AnaptysBio Generated Anti-LAG-3 (GSK40974386) [Member] AnaptysBio Generated Anti-LAG-3 (GSK40974386) Entity Interactive Data Current Entity Interactive Data Current Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Issuance of common stock from exercises of options and employee stock purchase plan Stock Issued During Period, Value, Stock Options Exercised Standby Letters of Credit Standby Letters of Credit [Member] Minimum Minimum [Member] Sagard Sagard Healthcare Royalty Partners, LP [Member] Sagard Healthcare Royalty Partners, LP 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two Royalties and milestones, agreement amount to be received Advance Future Royalties, Aggregate Payment, Threshold Advance Future Royalties, Aggregate Payment, Threshold Forfeitures and cancellations (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Reclassification Reclassification, Comparability Adjustment [Policy Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Balance at the beginning of the year Balance at the end of the year Unrecognized Tax Benefits Income Tax Authority [Domain] Income Tax Authority [Domain] Total deferred tax assets Deferred Tax Assets, Gross 10421 Building 10421 Pacific Center Court, San Diego, CA [Member] 10421 Pacific Center Court, San Diego, CA Laboratory equipment Laboratory Equipment [Member] Laboratory Equipment [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Gross Unrealized Gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Entity Address, State or Province Entity Address, State or Province 12 Months or Greater, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer Current liabilities: Liabilities, Current [Abstract] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Long-term restricted cash Restricted cash Restricted Cash and Cash Equivalents, Noncurrent General and administrative General and Administrative Expense Stockholders' Equity, Beginning Balance (in shares) Stockholders' Equity, Ending Balance (in shares) Shares, Outstanding Schedule of Reconciliation of Expected Statutory Federal Income Tax Provision and Actual Income Tax Provision Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Stock options exercisable, ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Equity Incentive Plans Share-based Payment Arrangement [Text Block] Royalty sales Net Sales Royalty Net Sales Royalty Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Leases Lessee, Leases [Policy Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Weighted average remaining contractual term, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Zejula and JEMPERLI Zejula And Anaptys Bio Generated JEMPERLI [Member] Zejula And Anaptys Bio Generated JEMPERLI Number of reportable segments Number of Reportable Segments Internal rate of return (as a percent) Advance Future Royalties, Internal Rate Of Return Advance Future Royalties, Internal Rate Of Return Accrued professional fees Accrued Professional Fees, Current Letters of credit outstanding Letters of Credit Outstanding, Amount Present value of lease liabilities Operating Lease, Liability Document Transition Report Document Transition Report Common stock, $0.001 par value, 500,000 shares authorized, 27,647 shares and 27,356 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Total other income (expense), net Nonoperating Income (Expense) Weighted average period remaining for amortization of unrecognized compensation cost (in years) Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Phase 1 clinical trial initiation Phase 1 Clinical Trial Initiation [Member] Phase 1 Clinical Trial Initiation [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Proceeds, contingent on annual sales milestones upfront (as a percent) Advance Future Royalties, Aggregate Payment, Threshold Percent Advance Future Royalties, Aggregate Payment, Threshold Percent Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Emerging Growth Company Entity Emerging Growth Company Milestone payments, contingent upon certain U.S. and European regulatory submissions and approvals (up to) Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals Revenue Recognition, Milestone Method, Contingent Upon Certain United States And European Regulatory Submissions And Approvals ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Schedule of Weighted Average Assumptions in Stock Option Valuations Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Auditor Name Auditor Name Cover [Abstract] Cover [Abstract] Cash payments under licensing agreements Payments For Upfront, Milestone, And Royalty Payments Payments For Upfront, Milestone, And Royalty Payments Short Term and Long Term Investments Marketable Securities, Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Schedule of Unrealized Loss and Fair Values in a Loss Position Schedule of Unrealized Loss on Investments [Table Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Income Tax Authority [Axis] Income Tax Authority [Axis] Income tax expense related to other comprehensive income OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Other comprehensive (loss) income: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Financial Instrument [Axis] Financial Instrument [Axis] Accrued expenses Total accrued expenses Accrued Liabilities, Current BMS Bristo-Meyers Squibb [Member] Bristo-Meyers Squibb [Member] Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Equity compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Licensing agreement, remaining life (in years) Collaboration License Agreement, Maximum Term Collaboration License Agreement, Maximum Term Office furniture and equipment Office Equipment [Member] Options Share-based Payment Arrangement, Option [Member] Equity [Abstract] Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Number of banks utilized for diversification of funds (in banks) Number Of Financial Institutions Utilized For Diversification Of Funds Number Of Financial Institutions Utilized For Diversification Of Funds Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Less than 12 Months, Fair Value Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months Common Stock Common Stock [Member] Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Loss from operations Operating Income (Loss) Zejula Zejula [Member] Zejula Employer contributions to the plan Defined Contribution Plan, Employer Discretionary Contribution Amount Sale of Future Royalties Sale Of Future Royalties Text Block [Text Block] Sale Of Future Royalties Text Block Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Current portion of operating lease liability Operating Lease, Liability, Current Gross Unrealized Losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Collaborative Research and Development Agreements Collaborative Arrangement Disclosure [Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Lease Agreement 10770 Wateridge Circle, San Diego, California 92121 [Member] 10770 Wateridge Circle, San Diego, California 92121 Agreement term following first commercial sale or expiration of the last to expire patent (in years) Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Revenue Recognition, Milestone Method, Agreement Term Following First Commercial Sale Or Expiration Of The Last To Expire Patent Purchase of investments Payments to Acquire Debt Securities, Available-for-sale Number of milestones achieved during period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Revenue Recognition, Milestone Method, Number Of Milestones Achieved During Period Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Equity compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount Other income (expense), net Other Nonoperating Income (Expense) Phase 2 clinical trial initiation Phase 2 Clinical Trial Initiation [Member] Phase 2 Clinical Trial Initiation [Member] Revenue recognition multiple deliverable arrangements upfront fee receivable Revenue Recognition, Multiple Deliverable Arrangements Upfront Fees Revenue Recognition, Multiple Deliverable Arrangements Upfront Fees Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Schedule of Milestones Achieved Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Aggregate intrinsic value, options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Schedule of Future Minimum Annual Obligations Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders’ equity Stockholders' Equity, Beginning Balance Stockholders' Equity, Ending Balance Stockholders' Equity Attributable to Parent Employer match, maximum contributions Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount Net operating loss carryforwards Operating Loss Carryforwards Balance Sheet Related Disclosures [Abstract] Balance Sheet Related Disclosures [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Liability Related to the Sale of Future Royalties Advance Future Royalties, Liability [Policy Text Block] Advance Future Royalties, Liability Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued City Area Code City Area Code Accounts payable and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Aggregate intrinsic value, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Entity Address, City or Town Entity Address, City or Town Property and equipment, useful life (in years) Property, Plant and Equipment, Useful Life Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Schedule of Activity Related to Unrecognized Tax Benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Commercial and corporate obligations Commercial And Corporate Obligations [Member] Commercial And Corporate Obligations [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Receivable related to issuance of common stock, upon exercise of stock options Receivable, Issuance Of Common Stock, Stock Options Exercised Receivable, Issuance Of Common Stock, Stock Options Exercised Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Measurement Frequency [Domain] Measurement Frequency [Domain] Anti-PD-1 (JEMPERLI/Dostarlimab) AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) [Member] AnaptysBio-generated Anti-PD-1 (JEMPERLI/Dostarlimab) Interest expense Interest Expense Annual increase in number of shares available for issuance (as a percent) Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Common Stock, Capital Shares Reserved For Future Issuance, Annual Increase, Percent Of Aggregate Shares Outstanding Lease liability Deferred Tax Assets, Lease Liability Deferred Tax Assets, Lease Liability Accumulated deficit Retained Earnings (Accumulated Deficit) Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Award expiration period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Total deferred tax liabilities Deferred Tax Liabilities, Gross Employer match, percent of contributions (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Match Accrued research and development expenses Accrued Research And Development Expenses, Current Accrued Research And Development Expenses, Current Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Non-cash interest expense recognized Noncash Interest Expense Recognized Noncash Interest Expense Recognized First BLA approval - second indication First Biologics License Application Approval Second Indication [Member] First Biologics License Application Approval Second Indication US Treasury Securities US Treasury Securities [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Registrant Name Entity Registrant Name Proceeds from issuance of common stock Proceeds from Stock Options Exercised Phase 3 clinical trial initiation - first indication Phase 3 Clinical Trial Initiation - First Indication [Member] Phase 3 Clinical Trial Initiation - First Indication Provision for income taxes Income tax benefit Income Tax Expense (Benefit) Royalties agreement, maximum annual royalty payout capacity Advance Future Royalties, Annual Sales Threshold Advance Future Royalties, Annual Sales Threshold Amendment Flag Amendment Flag Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total minimum payments required Lessee, Operating Lease, Liability, to be Paid Change in the valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Share-Based Compensation Share-based Payment Arrangement [Policy Text Block] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five Security deposit Security Deposit Unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Product and Service [Axis] Product and Service [Axis] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Schedule of Common Stock Reserved for Future Issuance Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Schedule Of Common Stock Reserved For Future Issuance [Table Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Entity Public Float Entity Public Float Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Weighted average grant date fair value per share (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Royalty percent on net sales (as a percent) Net Sales Royalty Percent Net Sales Royalty Percent 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Non-cash interest expense for the sale of future royalties Non-cash interest expense for the sale of future royalties Noncash Advance Future Royalties, Interest Expense Noncash Advance Future Royalties, Interest Expense Advance future royalties agreement term (in years) Advance Future Royalties, Agreement Term Advance Future Royalties, Agreement Term Statement [Line Items] Statement [Line Items] Weighted-Average Exercise Price per Share Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Long-term investments Debt Securities, Available-for-sale, Noncurrent Federal tax authority Domestic Tax Authority [Member] Revenue Recognition [Abstract] Revenue Recognition [Abstract] Schedule of Non-cash Stock-based Compensation Expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] Total Fair Value Debt Securities, Available-for-sale Counterparty Name [Domain] Counterparty Name [Domain] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Tax Period [Axis] Tax Period [Axis] License agreement, obligation payable period (in years) Collaboration License Agreement, Obligation Payable Period Collaboration License Agreement, Obligation Payable Period License costs Collaboration License Agreement, Upfront, Milestone And Royalty Expense Collaboration License Agreement, Upfront, Milestone And Royalty Expense Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Research credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Less: valuation allowance Deferred Tax Assets, Valuation Allowance Auditor Location Auditor Location Fair Value Debt Securities, Available-for-sale, Unrealized Loss Position Investments at fair value Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Cash And Cash Equivalents And Restricted Cash, Fair Value Disclosure Amortized Cost Debt Securities, Available-for-sale, Amortized Cost Employee Benefit Plan Retirement Benefits [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Document Annual Report Document Annual Report Comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Title of 12(b) Security Title of 12(b) Security Proceeds from issuance of common stock Proceeds from Issuance of Common Stock Total assets Assets Advance Future Royalties, Payment[Axis] Advance Future Royalties, Payment [Axis] Advance Future Royalties, Payment Deferred Tax Liabilities: Components of Deferred Tax Liabilities [Abstract] Director Director [Member] Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Phase 3 clinical trial initiation - second indication Phase 3 clinical Trial Initiation - Second Indication [Member] Phase 3 clinical Trial Initiation - Second Indication [Member] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Title of Individual [Axis] Title of Individual [Axis] Payments on notes payable Repayments of Notes Payable Document Type Document Type Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Balance Sheet Accounts and Supplemental Disclosures Supplemental Balance Sheet Disclosures [Text Block] Lease termination term (in years) Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Lessee, Operating Lease, Lease Not yet Commenced, Expiration Period Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Advance Future Royalties, Payment [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Research tax credit carryforwards Tax Credit Carryforward, Amount Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Schedule of Costs in Cash Flow Statement Lease, Cost [Table Text Block] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Increase in annual rent (as a percent) Annual Rent Increase Percent Annual Rent Increase Percent Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Loss per share, diluted (in dollars per share) Earnings Per Share, Diluted State tax authority State and Local Jurisdiction [Member] Amortization of right-of-use assets – operating Operating Lease, Right-of-Use Asset, Amortization Expense 2017 Equity Incentive Plan Equity Incentive Plan, 2017 [Member] Equity Incentive Plan, 2017 [Member] Rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Liability related to sale of future royalties Advance Future Royalties, Liability, Noncurrent Advance Future Royalties, Liability, Noncurrent Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accretion/amortization of investments, net Unrealized Gain (Loss) on Investments Net cash provided (used in) by financing activities Net Cash Provided by (Used in) Financing Activities Capital shares reserved for future issuance, increase (in shares) Common Stock, Capital Shares Reserved For Future Issuance, Increase Common Stock, Capital Shares Reserved For Future Issuance, Increase Collaboration And Exclusive License Agreement Collaboration And Exclusive License Agreement [Member] Collaboration And Exclusive License Agreement Debt Issuance Costs Debt, Policy [Policy Text Block] Award vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Interest or penalties on uncertain tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties [Roll Forward] Liabilities Related To Sale Of Future Royalties Fair Value Measurements and Available for Sale Investments Fair Value Disclosures [Text Block] Accounts payable Accounts Payable, Current Depreciation and amortization Depreciation, Depletion and Amortization Future minimum annual cash obligations, next 12 months Other Commitment, to be Paid, Year One Schedule of Assets and Liabilities that Require Fair Value Measurements on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Foreign tax authority Foreign Tax Authority [Member] Filing of the first MAA(2) - first indication Filing of MMA - First Indication [Member] Filing of MMA - First Indication Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Net deferred tax assets Deferred Tax Assets, Net, Before Valuation Allowance Deferred Tax Assets, Net, Before Valuation Allowance 2017 Employee Stock Purchase Plan Employee Stock Purchase Plan, 2017 [Member] Employee Stock Purchase Plan, 2017 [Member] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Financial Instruments [Domain] Financial Instruments [Domain] Document Period End Date Document Period End Date Filing of the first BLA(1) - first indication Filing of Biologics License Application - First Indication [Member] Filing of Biologics License Application - First Indication Entity Central Index Key Entity Central Index Key Non cash royalty revenue, for sale of future royalties Noncash Advance Future Royalties Revenue Noncash Advance Future Royalties Revenue Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Auditor Information [Abstract] Auditor Information [Abstract] Shares Subject to Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Deferred Tax Assets: Deferred Tax Assets, Gross [Abstract] Long-lived asset impairment charges Tangible Asset Impairment Charges Lease renewal term (in years) Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Research and development credits Deferred Tax Assets, Tax Credit Carryforwards, Research Income Statement Location [Domain] Income Statement Location [Domain] Decrease related to prior year tax positions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Total operating expenses Operating Expenses Royalty Agreement, up To $1. 0 billion Royalty Agreement, Up To $1. 0 billion [Member] Royalty Agreement, Up To $1. 0 billion Trading Symbol Trading Symbol Collaborative Research and Development Agreement Collaborative Arrangement [Member] Property and equipment, gross Property, Plant and Equipment, Gross Gross Unrealized Losses Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss At any time after 2027 Third Installment [Member] Third Installment Long Lived Assets Property, Plant and Equipment, Impairment [Policy Text Block] Liability related to sale of future royalties - beginning balance Liability related to sale of future royalties - ending balance Advance Future Royalties, Liabilities Advance Future Royalties, Liabilities Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Upfront license fee received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Revenue Recognition, Multiple-deliverable Arrangements, Upfront Fee Received Weighted average remaining contractual term, options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Research Tax Credit Carryforward Research Tax Credit Carryforward [Member] Entity Current Reporting Status Entity Current Reporting Status Net loss per common share: Earnings Per Share, Basic and Diluted [Abstract] Effective interest rate (as a percent) Advance Future Royalties, Interest Rate, Effective Percentage Advance Future Royalties, Interest Rate, Effective Percentage Issuance costs related to the sale of future royalties Issuance costs related to the sale of future royalties Advance Future Royalties, Issuance Costs Advance Future Royalties, Issuance Costs Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Income/(Loss) before Income Tax Provision (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Loss on disposal of tenant improvements and certain equipment Gain (Loss) on Disposition of Property Plant Equipment Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Allowance for credit losses Debt Securities, Available-for-sale, Allowance for Credit Loss Current assets: Assets, Current [Abstract] Common stock, shares reserved for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Income Taxes Income Tax, Policy [Policy Text Block] Unrealized losses on available-for-sale Debt Securities, Available-for-sale, Unrealized Loss Unrealized (loss) income on available for sale securities, net of tax of $0, $0, and $153, respectively OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax Entity Address, Postal Zip Code Entity Address, Postal Zip Code Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Shares issued under employee stock plans (in shares) Exercises (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted U.S. Income (Loss) from Continuing Operations before Income Taxes, Domestic During 2027 Second Installment [Member] Second Installment 2018 and after Tax Year 2018 and After [Member] Tax Year 2018 and After Recurring Fair Value, Recurring [Member] Income Taxes Income Tax Disclosure [Text Block] Amounts accrued for issuance costs related to the sale of future royalties Noncash Advance Future Royalties, Issuance Costs, Incurred but Not yet Paid Noncash Advance Future Royalties, Issuance Costs, Incurred but Not yet Paid Schedule of Activity Related to Stock Option Awards Share-based Payment Arrangement, Option, Activity [Table Text Block] Non-Cash Interest Expense on the Liability Related to the Sale of Future Royalties Noncash Advance Future Royalties, Interest Expense [Policy Text Block] Noncash Advance Future Royalties, Interest Expense Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block] Anti-TIM-3 (GSK4069889A/Cobolimab) AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) [Member] AnaptysBio Generated Anti-TIM-3 (GSK4069889A/Cobolimab) Schedule of Outstanding Potentially Dilutive Securities Excluded in the Calculation of Diluted Net Loss Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Excess tax benefits associated with the employee stock purchase plan Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Employee Stock Purchase Plan, Amount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Employee Stock Purchase Plan, Amount Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other income (expense), net: Nonoperating Income (Expense) [Abstract] Auditor Firm ID Auditor Firm ID Milestones achieved during period, amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Revenue Recognition, Milestone Method, Milestones Achieved During The Period, Amount Name of Property [Axis] Name of Property [Axis] Class of Stock [Line Items] Class of Stock [Line Items] Credit Facility [Axis] Credit Facility [Axis] Entity Address, Address Line One Entity Address, Address Line One Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Entity Address, Address Line Two Entity Address, Address Line Two Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] (Gain) loss on disposal of property and equipment, net of gain on lease termination Gain (Loss) On Disposal Of Property And Equipment, Net Of Gain On Lease Termination Gain (Loss) On Disposal Of Property And Equipment, Net Of Gain On Lease Termination Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] General and administrative General and Administrative Expense [Member] Basis of Consolidation Consolidation, Policy [Policy Text Block] Entity Shell Company Entity Shell Company Expected term (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Australian tax incentive receivable Increase (Decrease) in Income Taxes Receivable Total current liabilities Liabilities, Current ESPP Employee Stock [Member] Stock-based compensation APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member] AnaptysBio-generated Anti-PD-1 Antagonist Antibody (TSR-042) [Member] Amortization of issuance costs Amortization Of Advance Future Royalties Issuance Costs Amortization Of Advance Future Royalties Issuance Costs Money market funds Money Market Funds [Member] Employer match, percent of employees' gross pay (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Current Fiscal Year End Date Current Fiscal Year End Date Mutual funds Mutual Fund [Member] Statement [Table] Statement [Table] Accounting Pronouncements Recently Adopted New Accounting Pronouncements, Policy [Policy Text Block] Other, net Deferred Tax Assets, Other Statistical Measurement [Axis] Statistical Measurement [Axis] Expected income tax benefit at federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Less than 12 Months, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss Name of Property [Domain] Name of Property [Domain] Deferred Tax Assets, Operating Loss Carryforwards, State and Local Deferred Tax Assets, Operating Loss Carryforwards, State and Local Description of the Business Nature of Operations [Text Block] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Operating lease cost Operating Lease, Cost Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] 12 Months or Greater, Gross Unrealized Losses Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss 10455 Building 10455 Pacific Center Court in San Diego, California [Member] 10455 Pacific Center Court in San Diego, California Completion of first in vivo toxicology studies using GLPs In Vivo Toxicology Studies [Member] In Vivo Toxicology Studies [Member] Collaboration Revenue [Member] Collaboration Revenue